Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Major depressive disorder (MDD) is an emergent cause of personal and socio‐economic burden, both for the high prevalence of the disorder and the unsatisfying response rate of the available antidepressant treatments. No reliable predictor of treatment efficacy and tolerance in the single patient is available, thus drug choice is based on a trial and error principle with poor clinical efficiency. Among modulators of treatment outcome, genetic polymorphisms are thought to explain a significant share of the inter‐individual variability. The present review collected the main pharmacogenetic findings primarily about antidepressant response and secondly about antidepressant induced side effects, and discussed the main strengths and limits of both candidate and genome‐wide association studies and the most promising methodological opportunities and challenges of the field. Despite clinical applications of antidepressant pharmacogenetics are not available yet, previous findings suggest that genotyping may be applied in the clinical practice. In order to reach this objective, further rigorous pharmacogenetic studies (adequate sample size, study of better defined clinical subtypes of MDD, adequate covering of the genetic variability), their combination with the results obtained through complementary methodologies (e.g., pathway analysis, epigenetics, transcriptomics, and proteomics), and finally cost‐effectiveness trials are required. © 2013 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821 · cited 2×
“On the other hand, at the stringent genome-wide significance level of P 5 10 8 many markers that are truly but weakly associated with phenotype often fail to bedetected [Purcell et al., 2009].”
BackgroundEgan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 1×
“In humans theMet allele was associated with poorer episodic memory, abnormal hippocampal activation andmetabolism [Egan et al., 2003].”
BackgroundInflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 2×
“Brain is not a sanctuary for the immune system as hypothesized in the past, but inflammatory cytokines have been shown to access the brain and they can virtually interact with every pathophysiologic domain known to be involved in MDD, including neurotransmitter metabolism, neuroendocrine function, and neural plasticit…”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Allelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
The Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181
VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia
Sun, Y., Jin, K., Xie, L., Childs, J., Mao, X. O., Logvinova, A., & Greenberg, D. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317977 · Cited by 1,189
A functional polymorphism in the monoamine oxidase A gene promoter
Sabol, S. Z., Hu, S., & Hamer, D. (1998) · Human Genetics · doi:10.1007/s004390050816 · Cited by 1,079
Binder, E. B., Salyakina, D., Lichtner, P., Wochnik, G. M., Ising, M., Pütz, B., Papiol, S., Seaman, S., Lucae, S., Kohli, M. A., et al. (2004) · Nature Genetics · doi:10.1038/ng1479 · Cited by 977
Alonso, J., Angermeyer, M. C., & Lépine, J. P. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0047.2004.00325.x · Cited by 758
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., Epperson, C. N., Goddard, A., & Mason, G. F. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001021 · Cited by 553
MiR-16 Targets the Serotonin Transporter: A New Facet for Adaptive Responses to Antidepressants
Baudry, A., Mouillet-Richard, S., Schneider, B., Launay, J.-M., & Kellermann, O. (2010) · Science · doi:10.1126/science.1193692 · Cited by 480
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Kato, M., & Serretti, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.116 · Cited by 450 · cited 5×
“, 2006] (Supplementary Table I), and encouraging meta-analytic results were provided which suggested rs6311GG and rs6313CC genotypes as risk factors for side effects development [Kato and Serretti, 2010].”
ResultInfluentialSelf-citationVEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants
Warner-Schmidt, J. L., & Duman, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610282104 · Cited by 438
Cattaneo, A., Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K. J., Craig, I. W., Anacker, C., Zunsztain, P. A., McGuffin, P., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.191 · Cited by 436
Depression: an inflammatory illness?: Figure 1
Krishnadas, R., & Cavanagh, J. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301779 · Cited by 392 · cited 33×
“On the other hand, all glutamate NMDA and kainate receptor genes were not associated with antidepressant response by another study involving a large MDD sample [McMahon et al., 2006].”
BackgroundInfluentialRole of GSK3β in behavioral abnormalities induced by serotonin deficiency
Beaulieu, J.-M., Zhang, X., Rodriguiz, R. M., Sotnikova, T. D., Cools, M. J., Wetsel, W. C., Gainetdinov, R. R., & Caron, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711496105 · Cited by 368
Nutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366 · cited 2×
“Norepinephrine (NE) has a primary role in the regulation of energy and alertness [Nutt et al., 2007] and beta1 adrenergic receptor (ADRB1 gene) has been the most investigated candidate gene.”
BackgroundRada, J. A., Cornuet, P. K., & Hassell, J. R. (1993) · Experimental Eye Research · doi:10.1006/exer.1993.1081 · Cited by 345
Porcelli, S., Fabbri, C., & Serretti, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.10.003 · Cited by 331 · cited 2×
“Themost recentmeta-analysis focused on the effect of 5-HTTLPR (SLC6A4 gene) on antidepressant efficacy found an association between the polymorphism and treatment outcome in Caucasians, but underlined the risk of publication bias [Porcelli et al., 2012].”
BackgroundResultSelf-citationTardito, D., Perez, J., Tiraboschi, E., Musazzi, L., Racagni, G., & Popoli, M. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.1.7 · Cited by 303 · cited 1×
“Finally, both animal and human studies demonstrated that antidepressant treatment regulates CREB mRNA levels in different brain areas [Tardito et al., 2006].”
ResultWong, M.-L., Dong, C., Maestre-Mesa, J., & Licinio, J. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.59 · Cited by 295
Lekman, M., Laje, G., Charney, D., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Lipsky, R., Wisniewski, S. R., Manji, H., McMahon, F. J., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.026 · Cited by 284 · cited 2×
“…et al., 2007; Uher et al., 2009; Perlis et al., 2009a; Zobel et al., 2010; Sarginson et al., 2010b], while only some reports were positive (rs1360780, rs3800373, and rs4713916) [Binder et al., 2004; Kirchheiner et al., 2008], among which one was obtained in a large cohort [Lekman et al., 2008].”
ResultDopamine and depression: A review of recent evidence. I. Empirical studies
Willner, P. (1983) · Brain Research Reviews · doi:10.1016/0165-0173(83)90005-x · Cited by 273
Population genetic study of the brain-derived neurotrophic factor (BDNF) gene
Petryshen, T. L., Sabeti, P. C., Aldinger, K. A., Fry, B., Fan, J. B., Schaffner, S. F., Waggoner, S. G., Tahl, A. R., & Sklar, P. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.24 · Cited by 267 · cited 1×
“The first one is ethnic stratification, since considerable BDNF allele and haplotype diversity among global populations was found [Petryshen et al., 2010].”
BackgroundA psychoneuroimmunological review on cytokines involved in antidepressant treatment response
Janssen, D. G. A., Caniato, R. N., Verster, J. C., & Baune, B. T. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1103 · Cited by 240 · cited 1×
“Consistently, treatment outcome of MDD is influenced by the antidepressant inducedmodulation of cytokines, which occurs through a direct or indirect action on intracellular cyclic adenosyl monophosphate (cAMP), 5-HT metabolism, and HPA axis functioning [Janssen et al., 2010].”
BackgroundThe Effect of Paroxetine on 5-HT2A Receptors in Depression: An [18F]Setoperone PET Imaging Study
Meyer, J. H., Kapur, S., Eisfeld, B., Brown, G. M., Houle, S., DaSilva, J., Wilson, A. A., Rafi-Tari, S., Mayberg, H. S., & Kennedy, S. H. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.78 · Cited by 231 · cited 2×
“, 2011c] and antidepressant mechanisms of action [Meyer et al., 2001]: notably, 5-HT2A receptor blockade leads to rapid antidepressant effect in rodents [Pandey et al.”
BackgroundGenetic predictors of response to antidepressants in the GENDEP project
Uher, R., Huezo-Diaz, P., Perroud, N., Smith, R., Rietschel, M., Mors, O., Hauser, J., Maier, W., Kozel, D., Henigsberg, N., et al. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.12 · Cited by 226
Hranilovic, D., Stefulj, J., Schwab, S., Borrmann-Hassenbach, M., Albus, M., Jernej, B., & Wildenauer, D. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.029 · Cited by 224
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
Kwok, J. B. J., Hallupp, M., Loy, C. T., Chan, D. K. Y., Woo, J., Mellick, G. D., Buchanan, D. D., Silburn, P. A., Halliday, G. M., & Schofield, P. R. (2005) · Annals of Neurology · doi:10.1002/ana.20691 · Cited by 205 · cited 2×
“The T allele of the rs334558 ( 50 T/C) promoter SNP was associated with transcriptional strength [Kwok et al., 2005] and in bipolar depressed patients treated with total sleep deprivation the TT homozygote showed better response [Benedetti et al.”
BackgroundDopaminergic mechanism of antidepressant action in depressed patients
Willner, P., Hale, A. S., & Argyropoulos, S. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.12.010 · Cited by 169 · cited 2×
“, 2000]; (iii) antidepressant effects of SSRIs are reversed by acute administration of a D2 receptor selective antagonist [Willner et al., 2005].”
BackgroundBDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity
Bath, K. G., Jing, D. Q., Dincheva, I., Neeb, C. C., Pattwell, S. S., Chao, M. V., Lee, F. S., & Ninan, I. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.318 · Cited by 169 · cited 1×
“In mice, the Met/Met genotype did not show any increase in hippocampusBDNF levels during fluoxetine treatment andhad impaired survival of newly born cells in the dentate gyrus [Bath et al., 2012].”
BackgroundBrent, D., Melhem, N., Ferrell, R., Emslie, G., Wagner, K. D., Ryan, N., Vitiello, B., Birmaher, B., Mayes, T., Zelazny, J., et al. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09040576 · Cited by 138 · cited 2×
“…these results, a number of reports were negative [Peters et al., 2004; Levin et al., 2007; Baune et al., 2008b; Illi et al., 2009; Lin et al., 2009; Brent et al., 2010; Noro et al., 2010], as well as findings in the opposite direction exist [Hong et al., 2006; Yu et al., 2006; Baune et al., 2008b;…”
ResultGenetic Variants in FKBP5 Affecting Response to Antidepressant Drug Treatment
Kirchheiner, J., Lorch, R., Lebedeva, E., Seeringer, A., Roots, I., Sasse, J., & Brockmöller, J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.7.841 · Cited by 104 · cited 2×
“, 2010b], while only some reports were positive (rs1360780, rs3800373, and rs4713916) [Binder et al., 2004; Kirchheiner et al., 2008], among which one was obtained in a large cohort [Lekman et al.”
ResultKocabas, N. A., Antonijevic, I., Faghel, C., Forray, C., Kasper, S., Lecrubier, Y., Linotte, S., Massat, I., Mendlewicz, J., Noro, M., et al. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833d18f8 · Cited by 74 · cited 4×
“…studies mainly suggested a positive molecular heterosis effect [Tsai et al., 2003; Yoshida et al., 2007; Zou et al., 2010], together with a more favorable outcome in Met allele carriers [Choi et al., 2006; Alexopoulos et al., 2010; Taylor et al., 2010b; Kocabas et al., 2011a] (Table I).”
BackgroundInfluentialTsai, S.-J., Liou, Y.-J., Hong, C.-J., Yu, Y. W.-Y., & Chen, T.-J. (2008) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500486 · Cited by 66
Cited by
Biernacka, J. M., Sangkuhl, K., Jenkins, G., Whaley, R. M., Barman, P., Batzler, A., Altman, R. B., Arolt, V, Brockmöller, J., Chen, C. H., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.47 · Cited by 140
Lueken, U., Zierhut, K. C., Hahn, T., Straube, B., Kircher, T., Reif, A., Richter, J., Hamm, A., Wittchen, H.-U., & Domschke, K. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.04.005 · Cited by 133
Blood biomarkers and treatment response in major depression
Mora, C., Zonca, V., Riva, M. A., & Cattaneo, A. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1470927 · Cited by 107
Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications
Fabbri, C., & Serretti, A. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0594-9 · Cited by 84
Self-citationARPNet: Antidepressant Response Prediction Network for Major Depressive Disorder
Chang, B., Choi, Y., Jeon, M., Lee, J., Han, K.-M., Kim, A., Ham, B.-J., & Kang, J. (2019) · Genes · doi:10.3390/genes10110907 · Cited by 35
“Several studies [8–12] have been conducted to identify the effects of genetic variants on antidepressant response.”
Background
Metadata
- Authors
- Fabbri, C., Di Girolamo, G., & Serretti, A.
- Venue
- American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Publisher
- Wiley
- Published
- 2013-07-12
- Volume
- 162
- Issue
- 6
- Pages
- 487-520
- ISSN
- 1552-4841 (ISSN-L)
- 1552-485X
- OpenAlex
- W2001279805
- Cited by
- 82
- References
- 36
- FWCI
- 12.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.